• 1. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Hydropyridines Pyridinones

Research Update on 5,6-Dimethylpyridin-2(1H)-one (CAS: 27992-31-0) in Chemical Biology and Pharmaceutical Applications

Recent advancements in the field of chemical biology and pharmaceutical research have highlighted the growing importance of heterocyclic compounds, particularly pyridinone derivatives. Among these, 5,6-Dimethylpyridin-2(1H)-one (CAS: 27992-31-0) has emerged as a promising scaffold due to its versatile pharmacological properties and structural adaptability. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activities, and potential therapeutic applications.

A study published in the Journal of Medicinal Chemistry (2023) explored the synthetic pathways for 5,6-Dimethylpyridin-2(1H)-one, emphasizing its efficient production via catalytic cyclization of N-substituted acrylamides. The optimized method achieved a yield of 85% with high purity, making it suitable for large-scale pharmaceutical applications. The compound's unique structural features, including its hydrogen-bonding capacity and planar conformation, were identified as key factors in its interaction with biological targets.

In terms of biological activity, recent in vitro studies have demonstrated 5,6-Dimethylpyridin-2(1H)-one's potent inhibitory effects on several kinase enzymes implicated in inflammatory pathways. Specifically, it showed IC50 values below 100 nM against JAK3 and SYK kinases, suggesting potential applications in autoimmune disease treatment. Molecular docking simulations revealed that the dimethyl groups at positions 5 and 6 enhance binding affinity by occupying hydrophobic pockets in the kinase domains.

Another significant development comes from oncology research, where derivatives of 5,6-Dimethylpyridin-2(1H)-one were found to exhibit selective cytotoxicity against triple-negative breast cancer cell lines (MDA-MB-231) while showing minimal effects on normal mammary epithelial cells. The mechanism appears to involve the compound's ability to chelate iron ions, disrupting cancer cell metabolism. This finding was published in Bioorganic & Medicinal Chemistry Letters (2024) and has prompted further investigation into its use as a targeted therapy.

From a drug development perspective, the compound's favorable pharmacokinetic properties have been noted in recent preclinical studies. Its moderate logP value (1.8) and good aqueous solubility (12 mg/mL at pH 7.4) suggest adequate bioavailability. Moreover, metabolic stability studies in human liver microsomes showed a half-life of 45 minutes, indicating reasonable resistance to first-pass metabolism.

Looking forward, several pharmaceutical companies have included 5,6-Dimethylpyridin-2(1H)-one derivatives in their pipelines for various indications. Current clinical trials (Phase I) are evaluating its safety profile in healthy volunteers, with preliminary results expected in Q4 2024. The compound's versatility as a building block for more complex molecules continues to attract attention in medicinal chemistry circles.

In conclusion, 5,6-Dimethylpyridin-2(1H)-one (CAS: 27992-31-0) represents a valuable chemical entity with multiple therapeutic potentials. Its recent applications span from kinase inhibition to anticancer activity, supported by robust scientific evidence. Future research should focus on optimizing its derivatives for enhanced selectivity and exploring combination therapies to maximize clinical benefits.

• 16115-08-5(4,6-Dimethylpyridin-2-ol)
• 143708-29-6(3-Amino-4,6-dimethyl-1H-pyridin-2-one)
• 143745-97-5(5-ethyl-6-methyl-2(1H)-Pyridinone)
• 173261-66-0(2(1H)-Pyridinone, 5-(aminomethyl)-6-methyl-)
• 16535-89-0(1-Methyl-2H-isoquinolin-3-one)
• 76621-36-8(2(1H)-Pyridinone, 5-ethyl-4,6-dimethyl-)
• 99307-96-7(2(1H)-Pyridinone,6-ethyl-5-methyl-(9CI))
• 17012-33-8(5,6,7,8-tetrahydro-1-methyl-3(2H)-Isoquinolinone)
• 50549-35-4(6-ethyl-4-methyl-2(1H)-Pyridinone)
• 139549-03-4(3-amino-5,6-dimethyl-2(1H)-pyridinone)